EA202192117A1 - Способ лечения множественной миеломы - Google Patents
Способ лечения множественной миеломыInfo
- Publication number
- EA202192117A1 EA202192117A1 EA202192117A EA202192117A EA202192117A1 EA 202192117 A1 EA202192117 A1 EA 202192117A1 EA 202192117 A EA202192117 A EA 202192117A EA 202192117 A EA202192117 A EA 202192117A EA 202192117 A1 EA202192117 A1 EA 202192117A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- multiple myeloma
- subject
- treatment
- administering
- molecular weight
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 4
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 3
- 150000003384 small molecules Chemical class 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812002P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/019884 WO2020176610A1 (en) | 2019-02-28 | 2020-02-26 | Method for treating a multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192117A1 true EA202192117A1 (ru) | 2021-11-23 |
Family
ID=72238680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192117A EA202192117A1 (ru) | 2019-02-28 | 2020-02-26 | Способ лечения множественной миеломы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220143016A1 (enExample) |
| EP (1) | EP3931196A4 (enExample) |
| JP (1) | JP2022521801A (enExample) |
| CN (1) | CN113710670A (enExample) |
| AU (1) | AU2020227748A1 (enExample) |
| BR (1) | BR112021016747A2 (enExample) |
| CA (1) | CA3131249A1 (enExample) |
| EA (1) | EA202192117A1 (enExample) |
| IL (1) | IL285800A (enExample) |
| MX (1) | MX2021010398A (enExample) |
| WO (1) | WO2020176610A1 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (enExample) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| EP2624818B1 (en) * | 2010-10-05 | 2017-04-05 | Fresenius Kabi USA, LLC | Bortezomib formulations stabilised with boric acid |
| PH12015501130B1 (en) * | 2012-11-21 | 2023-01-27 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| MX370588B (es) * | 2013-08-30 | 2019-12-16 | Ptc Therapeutics Inc | Inhibidores de la bmi-1 de pirimidina sustituida. |
| JP2021535198A (ja) * | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| KR20210151061A (ko) * | 2019-03-11 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형 |
-
2020
- 2020-02-26 AU AU2020227748A patent/AU2020227748A1/en not_active Abandoned
- 2020-02-26 BR BR112021016747-1A patent/BR112021016747A2/pt not_active Application Discontinuation
- 2020-02-26 CN CN202080030185.4A patent/CN113710670A/zh active Pending
- 2020-02-26 WO PCT/US2020/019884 patent/WO2020176610A1/en not_active Ceased
- 2020-02-26 EP EP20762789.4A patent/EP3931196A4/en active Pending
- 2020-02-26 JP JP2021550168A patent/JP2022521801A/ja active Pending
- 2020-02-26 US US17/433,106 patent/US20220143016A1/en not_active Abandoned
- 2020-02-26 EA EA202192117A patent/EA202192117A1/ru unknown
- 2020-02-26 CA CA3131249A patent/CA3131249A1/en active Pending
- 2020-02-26 MX MX2021010398A patent/MX2021010398A/es unknown
-
2021
- 2021-08-23 IL IL285800A patent/IL285800A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220143016A1 (en) | 2022-05-12 |
| WO2020176610A1 (en) | 2020-09-03 |
| EP3931196A4 (en) | 2022-12-14 |
| AU2020227748A1 (en) | 2021-09-16 |
| MX2021010398A (es) | 2022-01-18 |
| CN113710670A (zh) | 2021-11-26 |
| CA3131249A1 (en) | 2020-09-03 |
| EP3931196A1 (en) | 2022-01-05 |
| JP2022521801A (ja) | 2022-04-12 |
| WO2020176610A8 (en) | 2021-08-12 |
| IL285800A (en) | 2021-10-31 |
| BR112021016747A2 (pt) | 2021-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| EA202190581A1 (ru) | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| GEAP202215479A (en) | Magl inhibitors | |
| EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| BR112015013123A2 (pt) | inibidores de beta-lactamase | |
| MX389999B (es) | Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| EA201591362A1 (ru) | Соединения и способы лечения бактериальных инфекций | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| EA201792287A1 (ru) | Способы лечения рака | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MX389692B (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc. | |
| MX2022007626A (es) | Combinaciones. | |
| CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. | |
| JOP20210216A1 (ar) | علاج السرطان | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2024003499A (es) | Peróxidos cíclicos como profármacos para el suministro selectivo de agentes. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof |